PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
In this open-label phase II study, patients will be scheduled for neoadjuvant treatment with
PD-1 inhibitors (Camrelizumab) plus VEGF inhibitor (Apatinib) for dMMR/MSI-H colorectal
cancer staged as locally advanced (cT3-4N+/-M0 for rectal cancer, cT4 or cT3 with extramural
extension ≥5mm for colon cancer). Radiological evaluation will be preformed after 4 cycles of
treatment. Patients with rectal cancer who achieve complete clinical response will be offered
the choice of Watch & Wait.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Guangdong Provincial Hospital of Traditional Chinese Medicine Guangdong Provincial People's Hospital